Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: anticancer antibodies - Patrys

Drug Profile

Research programme: anticancer antibodies - Patrys

Alternative Names: 3E10; 5C6; 5C6 antibody; Deoxymab; Deoxymab 3E10; Deoxymab-1; PAT DX1 NP; PAT-BA1; PAT-BA2; PAT-BA4; PAT-CM1; PAT-DX1; PAT-NM1; PAT-NM2; PAT-PM1; PAT-PM2; PAT-SM3; PAT-SM4; PAT-SM5

Latest Information Update: 21 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator OncoMab GmbH; Patrys; Yale University
  • Developer Patrys; Yale University
  • Class Antibodies; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Cell death stimulants; DNA repair inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 22 Jul 2019 Pharmacodynamics data from a preclinical trial in Glioblastoma released by Patrys
  • 29 Mar 2019 Pharmacodynamics data from preclinical studies in Cancer presented at the 110th Annual Meeting of the American Association for Cancer Research (AACR-2019)
  • 26 Mar 2019 Patrys has patent protection for 5C6 antibody in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top